| Sulanda (surufatinib) / Hutchmed |
NCT05056116: A Safety and Efficacy Study of Surufatinib Combination With Toripalimab in Patients With Recurrent Biliary Tract Cancer |
|
|
| Recruiting | N/A | 30 | RoW | Surufatinib Toripalimab, Surufatinib/JS001 | The Affiliated Hospital of Xuzhou Medical University | Biliary Tract Cancer | 06/22 | 06/24 | | |
NCT06378580: The Prognostic Impact of Surufatinib for the Treatment of Advanced Pancreatic Ductal Adenocarcinoma |
|
|
| Completed | N/A | 72 | RoW | Surufatinib combine immune checkpoint inhibitor, AG/FOLFIRINOX | Luo Cong | Pancreatic Cancer | 07/23 | 04/24 | | |
NCT05013515: Efficacy and Safety of Neoadjuvant Surufatinib for Patients With Salivary Gland Carcinomas |
|
|
| Recruiting | N/A | 20 | RoW | Surufatinib, radiotherapy or chemoradiotherapy | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Salivary Gland Carcinomas | 09/22 | 06/24 | | |
ChiCTR2200060954: A single-arm, open-label, single-center, real-world study of surufatinib combined PD-1 inhibitor in patients with small cell lung cancer who failed first-line chemotherapy |
|
|
| Not yet recruiting | N/A | 20 | | None | Xi'an Jiaotong University First Affiliated Hospital; Xi'an Jiaotong University First Affiliated Hospital, self-funding | Small-cell lung cancer | | | | |
| No Longer Available | N/A | | US | Surufatinib | Hutchmed | Neuroendocrine Tumors | | | | |
NCT06156332: A Study of Surufatinib Combined With Serplulimab in the Treatment of Advanced Solid Tumors With Neuroendocrine Differentiation That Failed Standard Therapy |
|
|
| Not yet recruiting | N/A | 39 | NA | surufatinib、serplulimab | Shanghai Changzheng Hospital | Advanced Solid Tumors With Neuroendocrine Differentiation | 01/25 | 01/27 | | |
NCT06313554: Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 63 | NA | Surufatinib、Toripalimab、Gemcitabine、Oxaliplatin | Fudan University | Intrahepatic Cholangiocarcinoma | 05/24 | 05/27 | | |
NCT05697237: Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma |
|
|
| Not yet recruiting | N/A | 60 | NA | Carrelizumab, Solfantinib | First Affiliated Hospital Xi'an Jiaotong University | Cholangiocarcinoma | 06/24 | 12/24 | | |
| Not yet recruiting | N/A | 32 | NA | Surufatinib | Qilu Hospital of Shandong University, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Affiliated Hospital of Qingdao University, Yantai Yuhuangding Hospital, Weifang People's Hospital | Neuroendocrine Tumor Grade 3 | 06/24 | 06/25 | | |
ChiCTR2200056017: Single-arm, open, multicenter clinical study of Surufatinib combined with Camrelizumab in second-line treatment of patients with advanced biliary tract cancer |
|
|
| Not yet recruiting | N/A | 42 | | Surufatinib combined with Camrelizumab | Xiangyang Central Hospital; Xiangyang First People's Hospital, Not stated | biliary tract cancer | | | | |
ChiCTR2300069581: A prospective observational study of Sulfatinib plus albumin paclitaxel and gemcitabine regimen for transformation therapy of locally advanced pancreatic cancer |
|
|
| Recruiting | N/A | 40 | | Sofantinib combined with albumin bound paclitaxel and gemcitabine hydrochloride | The First Affiliated Hospital of Xi'an Jiaotong University; The First Affiliated Hospital of Xi'an Jiaotong University, self-funding | Pancreatitc cancer | | | | |
ChiCTR2100053385: A study evaluating the conversion therapy of surufatinib in combination with chemotherapy in patients with unresectable pancreatic neuroendocrine tumor (PNET) |
|
|
| Recruiting | N/A | 24 | | Surufatinib+Capecitabine + Temozolomide ;Surufatinib+Etoposide+cisplatin | West China Hospital of Sichuan University; West China Hospital of Sichuan University, Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd. | pancreatic neuroendocrine tumor | | | | |
ChiCTR2100052020: Efficacy and safety of surufatinib as salvage therapy for patients with tyrosine kinase inhibitor - refractory differentiated thyroid cancer: a single-arm, exploratory multicenter clinical study |
|
|
| Not yet recruiting | N/A | 60 | | Surufatinib 300 mg, oral taken once daily for 4 weeks | Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospita, Self-funded | Differentiated thyroid cancer | | | | |
ChiCTR2300071563: A phase Ⅱ study to evaluate the efficacy and safety of Surufatinib ,Zimberelimab combined with nab-paclitaxel in advanced triple-negative breast cancer |
|
|
| Recruiting | N/A | 29 | | Surufatinib :250mg QD P.O, , Zimberelimab :360mg I.V D1 , , nab-paclitaxel:100mg/m2 I.V D1,D8. | Provincial Hospital Affiliated to Shandong First Medical University; Provincial Hospital Affiliated to Shandong First Medical University, Self-financing | TNBC | | | | |
ChiCTR2300072634: SHR1701 in combination with Surufatinib as late-line treatment in advanced colorectal cancer |
|
|
| Not yet recruiting | N/A | 38 | | SHR1701 and Surufatinib ;SHR1701 and Surufatinib | Shanghai East Hospital; Shanghai East Hospital, Fund | colorectal cancer | | | | |
ChiCTR2300073815: Single-arm, single-center, observational study of surufatinib combined with chemotherapy in the first-line treatment of extensive small cell lung cancer |
|
|
| Not yet recruiting | N/A | 30 | | Sofantinib combined with chemotherapy | The Second Affiliated Hospital of Shandong First Medical University; The Second Affiliated Hospital of Shandong First Medical University, self-raised | Small cell lung cancer | | | | |
ChiCTR2200063336: A prospective, single-arm clinical study evaluating the efficacy and safety of surufatinib combined with standard chemotherapy in patients with advanced gastric/gastroesophageal junction adenocarcinoma who failed first-line therapy |
|
|
| Not yet recruiting | N/A | 35 | | surufatinib combined with standard chemotherapy | Renji Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Jiao Tong University School of Medicine, Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Company Ltd. | gastric cancer | | | | |
ChiCTR2300067751: Prospective study of Surufatinib combined with anti-PD-1 monoclonal antibody in preventing recurrence of Biliary Tract Cancer after radical resection |
|
|
| Not yet recruiting | N/A | 40 | | PD-1 + Surufatinib | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hutchison Whampoa Pharmaceutical (Shanghai) Co., LTD | Biliary Tract Cancer | | | | |
ChiCTR2300074531: A prospective, single-arm, multicenter clinical study of cadonilimab combined with surufatinib in the treatment of progress advanced soft tissue sarcoma after system chemotherapy |
|
|
| Not yet recruiting | N/A | 99 | | ① Cadonilimab was administered by intravenous infusion at a dose of 6mg/kg every 2 weeks. ② Surufatinib capsules: 200mg (4 capsules) each time, can be taken with a low-fat meal or orally on an empty stomach, once a day, continuous medication. | Shanghai Tongren Hospital; Shanghai Tongren Hospital, cadonilimab：Kangfang Biopharmaceutical Co., Ltd surufatinib：Hutchison MediPharma Co., Ltd | soft tissue sarcoma | | | | |
